Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in June 2011 and is headquartered in Irvine, CA.
相关临床试验
14
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
7.1%
已完成
7
50.0%
Enrolling By Invitation
1
7.1%
招募中
5
35.7%
暂无批准数据
- The VIAFORT trial, the first prospective study to include inferior vena cava, iliac, and femoral veins, enrolled 89 patients with thrombotic disease and achieved an 83.4% primary patency rate at 12 months. - Despite 94.3% of patients having lesions spanning three vessel regions, vessel-specific patency rates reached 96.5% in the IVC, 88.9% in the left iliofemoral, and 89.8% in the right iliofemoral regions. - The trial reported no stent migrations, fractures, vascular injuries, clinically significant pulmonary embolisms, device-related deaths, or major bleeding events within the study period. - Results position the GORE VIABAHN FORTEGRA Venous Stent as a reliable treatment option for complex deep venous obstruction cases requiring multi-vessel intervention.
- Stryker's newly launched Artix Thrombectomy System combines mechanical thrombectomy and aspiration capabilities, offering a novel solution for treating arterial blood clots in peripheral vessels. - The system features an innovative 8 Fr. low-profile design with a covered nitinol mesh funnel, specifically engineered to minimize clot migration risks during arterial thrombectomy procedures. - Initial clinical implementation demonstrates promising results, with physicians reporting potential to replace traditional open surgical repairs in many arterial cases.
• Large-bore mechanical thrombectomy demonstrates superiority over catheter-directed thrombolysis in acute intermediate-risk pulmonary embolism, reducing clinical deterioration and ICU stays. • Percutaneous transmural arterial bypass shows sustained patency at 3 years for complex superficial femoropopliteal lesions, offering a bypass alternative without open surgery. • The FDA approved a bioresorbable scaffold for below-the-knee infrapopliteal disease, showing safety and efficacy at 1 year compared to angioplasty alone.
- The PROMISE II trial demonstrates sustained limb salvage and wound healing at 2 years using the LimFlow System for no-option CLTI patients. - DETOUR2 study reveals the durability of percutaneous transmural arterial bypass with the DETOUR System for complex femoropopliteal disease, showing promising 3-year outcomes. - SIRONA trial's post-hoc analysis suggests sirolimus-coated balloons as a viable alternative to paclitaxel-coated balloons in femoropopliteal angioplasty. - ELEGANCE registry indicates that drug-eluting devices in endovascular PAD treatment yield excellent 1-year outcomes in underrepresented patient groups.
- The PROMISE II trial demonstrates sustained limb salvage and wound healing at two years using the LimFlow System for no-option CLTI patients. - DETOUR2 study shows percutaneous transmural arterial bypass with the DETOUR System offers durable outcomes for complex femoropopliteal lesions at three years. - The LIFE-BTK trial indicates the Global Limb Anatomic Staging System (GLASS) effectively identifies CLTI patients at higher risk for adverse events.
• The Esprit BTK scaffold demonstrated superior long-term outcomes in treating chronic limb-threatening ischemia compared to percutaneous transluminal angioplasty. • Shockwave Javelin Peripheral IVL catheter met efficacy and safety goals, significantly reducing stenosis in severely calcified lesions. • TCAR using the ENROUTE system proves safe and effective for carotid stenosis in standard-surgical-risk patients, with low stroke and cranial nerve injury rates.
• The Esprit BTK scaffold demonstrated superior long-term outcomes compared to PTA in treating chronic limb-threatening ischemia, with a 61.5% limb salvage and primary patency rate at 2 years. • The Shockwave Javelin Peripheral IVL catheter met efficacy and safety goals, achieving a 99% effectiveness rate and 1.1% major adverse event rate at 30 days in treating calcified lesions. • Computer-assisted vacuum thrombectomy (CAVT) for intermediate-risk pulmonary embolism significantly reduced hospital length of stay and complications compared to other treatments. • Mechanical thrombectomy with the ClotTriever System for DVT showed significant symptom relief and improved vessel function, with 81.5% of limbs showing no postthrombotic syndrome at 2 years.
- Edwards Lifesciences' tricuspid valve replacement device met its primary endpoint in a trial, showing improvement in patient-reported quality of life but no significant mortality benefit at 12 months. - Medtronic's Symplicity Spyral renal denervation device demonstrated sustained blood pressure reduction over two years compared to a sham procedure in hypertension patients. - Inari Medical's Flowtriever thrombectomy device showed superiority to catheter-directed thrombolysis in intermediate-risk pulmonary embolism patients, reducing ICU admissions and length of stay.
- The PEERLESS trial demonstrated that Inari Medical's FlowTriever system significantly reduced clinical deterioration and therapy escalation compared to catheter-directed thrombolytics (CDT) in intermediate-risk pulmonary embolism (PE) patients. - FlowTriever patients experienced faster recovery, with improved clinical symptoms and hemodynamics, shorter hospital stays, and fewer 30-day readmissions compared to those treated with CDT. - The study reported zero patient deaths at discharge or seven days in the FlowTriever arm, along with a low 0.4% all-cause mortality rate at 30-day follow-up, highlighting the device's safety profile. - These findings position FlowTriever as a potentially superior interventional tool for managing intermediate-risk PE, suggesting a new standard for clinically meaningful endpoints in PE treatment.
• The FDA granted traditional approval to Sirturo (bedaquiline) for treating rifampin- and isoniazid-resistant tuberculosis in adults and children, based on Phase 3 STREAM study data. • mResvia, an mRNA-based vaccine, received FDA approval for preventing lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults aged 60 years and older. • Capvaxive, a pneumococcal 21-valent conjugate vaccine, was approved for preventing invasive disease and pneumonia caused by Streptococcus pneumoniae in adults 18 years and older. • Several critical care medical devices, including infusion pumps and chest compression devices, were recalled due to potential for serious adverse health consequences.
